In RCC cells, FBXO22 has no any effect on proliferation, but FBXO22 restricted RCC cell motility and reversed EMT via an increase of the activity of TIMP-1 and an decrease of MMP-9 expression as well as a reduction of VEGF secretion50. Here, VEGFA is linked to renal cell carcinoma.